How Long Does COVID Vaccine Immunity Actually Last?

COVID vaccine immunity does not have a single expiration date. Antibodies in your blood start declining within weeks of a shot and can lose roughly 90% of their peak levels within three months, yet protection against hospitalization and death persists far longer than protection against catching the virus at all. That gap exists because your immune system is not one thing; it is a layered defense, and each layer fades at its own pace. The practical answer depends on which layer you are asking about, which variant is circulating, and whether you have also been infected.

How Fast Antibodies Drop After Vaccination

The most visible part of vaccine immunity is the surge in antibodies that follows each dose. After two mRNA doses, average anti-spike antibody levels peak at around 2,300 BAU/mL within the first month. But these antibodies have a half-life of about 60 days, meaning roughly half the antibodies disappear every two months.¹ A separate study measuring the kinetics of this decline found that vaccination led to about 90% loss in antibody levels within 90 days, a rate strikingly similar to what happens after a mild natural infection.²

A booster dose changes the picture substantially. After a third mRNA dose, peak antibody levels roughly triple compared to the two-dose peak, reaching about 7,200 BAU/mL. More importantly, the half-life nearly doubles to about 100 days, so antibodies stick around meaningfully longer.¹ Modeling work supports this general pattern: each successive booster appears to slow the rate at which antibodies drop, maintaining detectable levels for a longer stretch.³ Still, the decline is relentless. A longitudinal study tracking antibody titers out to a year found that across different vaccine types, antibody levels kept dropping at every measurement point, with protection against reinfection becoming statistically insignificant by 12 months in people who had not been boosted or infected.⁴

Why You Can Still Be Protected Even When Antibodies Are Low

Antibody levels are easy to measure, which is why they dominate headlines. But they are not the whole immune response. Protection against severe disease lasts considerably longer than protection against getting infected, and that gap reveals the work of other immune components.

A systematic review and meta-regression covering studies from the pandemic’s first few years found that while vaccine effectiveness against infection declined steadily over time and dropped further with each new variant, protection against severe outcomes was consistently more durable.⁵ In concrete terms, against the Omicron variant, the primary vaccine series offered only about 20% protection against infection overall, and by six months that had dropped to near zero. But protection against severe Omicron disease was still around 64% at three months and about 49% at six months. A booster pushed severe-disease protection up to roughly 86%.⁶ A European meta-analysis found a similar pattern: six months after the primary series, vaccines still offered over 50% protection against severe Omicron outcomes, and boosters restored that to nearly 88%, holding at about 79% three months later.⁷

The reason protection against hospitalization outlasts protection against infection comes down to T cells and memory B cells. These take longer to mobilize than circulating antibodies, so they cannot always prevent you from getting infected. But once a virus establishes itself and starts causing real damage, these slower-acting defenders step in to limit how sick you get.

T Cells and Memory B Cells as the Durable Backbone

Vaccination with mRNA vaccines triggers a sustained CD4+ and CD8+ T cell response. These cells appear before antibody levels have even peaked, develop markers of long-lived memory, and survive the natural contraction phase in which most short-lived immune cells die off. Research on the Pfizer vaccine showed that these T cells persisted for at least six months with a stem cell memory profile, meaning they can self-renew and rapidly produce fresh waves of virus-fighting cells when needed.⁸ A broader review of T cell memory after vaccination confirmed that these stem cell memory T cells are found in most vaccinated individuals and may serve as an early indicator that the immune system has built effective long-term memory.⁹

An interesting detail from that same review: additional booster doses had little effect on the frequency of spike-specific CD8+ T cell memory, including the stem cell memory pool. The T cell compartment appeared to plateau after the initial vaccine course and held steady through three and four booster doses. This suggests that while boosters are crucial for refreshing antibody levels, the T cell side of immunity may be largely “set” after the first course.

Memory B cells contribute differently. After vaccination, B cells undergo a process called affinity maturation in specialized structures within your lymph nodes, gradually learning to produce better and more targeted antibodies. Studies found that this process continued in lymph nodes for at least 12 weeks after a booster, with the B cells progressively acquiring more mutations in their antibody genes, effectively getting better at recognizing the virus over time.¹⁰ Other work confirmed that this germinal center B cell response persisted in draining lymph nodes for at least six months in some individuals.¹¹ This ongoing maturation is one reason why memory B cells, even months later, can produce antibodies that are actually better at neutralizing the virus than the antibodies your body made right after vaccination.

Hybrid Immunity and Why Prior Infection Changes the Timeline

If you have been both vaccinated and infected, your immune response is broader and more durable than either alone. This “hybrid immunity” produces higher levels of neutralizing antibodies and a wider range of immune memory.¹² A 12-month study tracked different groups of people and found that those who were infected and then vaccinated maintained stable antibody levels above the protective threshold throughout the entire year and had significantly longer infection-free intervals before catching COVID again, compared to people who were only vaccinated or only infected.¹³

Given that most people alive today have been both vaccinated and infected at least once, the real-world immunity most of us carry is hybrid immunity, not pure vaccine-derived immunity. The neat timelines from clinical trials of naive (never-infected) individuals do not fully apply to most people anymore. Your actual level of protection is likely better than the vaccine-only numbers suggest, though it is still waning and still variant-dependent.

How Variants Erode Protection

Even with strong antibody levels, a new variant can slip past defenses that were trained on an older version of the virus. This is not just a theoretical concern. Research measuring serum neutralizing activity showed substantial drops when antibodies raised against earlier strains were tested against Omicron subvariants like JN.1, KP.2, and XBB.1.5.¹⁴ The virus evolves faster than our antibodies can keep up, which is why protection against infection fades so quickly with each wave, even when antibody levels have not fully dropped.

This is where vaccine updates matter. Updated boosters targeting newer variants help, but they run into a complication called immune imprinting. Your immune system tends to boost the antibodies it already has from prior exposures rather than generating entirely new ones against the updated target. After an XBB.1.5-targeted booster, researchers found that the antibodies produced were predominantly cross-reactive ones originally raised against the ancestral Wuhan strain, not genuinely new antibodies specific to XBB.1.5.¹⁴ People who had received fewer ancestral-strain vaccinations before the updated booster showed significantly greater fold-increases in variant-specific neutralization, suggesting that more prior exposures to the old strain made the imprinting effect stronger.¹⁵

A large cohort study in Qatar added a real-world dimension to this concern. Protection against infection waned gradually after a booster and was negligible by the sixth month. Beyond that point, people who had received the booster actually had slightly higher infection rates than those who had only completed the primary series, possibly because imprinting had narrowed their immune response against newer Omicron sublineages like BA.4/BA.5. The study noted that this trend appeared only after booster protection had fully waned and coincided with the arrival of more immune-evasive subvariants, though the sample sizes at those late timepoints were small and confidence intervals wide.¹⁶ There was no evidence that imprinting compromised protection against severe disease, which remained intact.

Who Loses Protection Faster

Age is probably the single biggest factor in how quickly vaccine immunity fades. Older adults generate weaker initial responses and lose them more rapidly. One study found that booster protection against severe COVID was strong in younger adults, with an adjusted odds ratio of 0.16, meaning roughly an 84% reduction in odds of severe disease. In elderly individuals, the same booster showed a much smaller and statistically non-significant benefit.¹⁷ A longitudinal study of adults aged 60 and above found that older age was associated with lower antibody levels at around six months post-vaccination, though the relationship weakened after adjusting for other factors.¹⁸

Sex also plays a role. A systematic review found that women generally produced higher antibody levels and stronger initial immune responses than men after mRNA vaccination. But women also experienced a more rapid decline in those antibodies over time, so the gap narrows as months pass.¹⁹

mRNA Versus Viral Vector Vaccines

Vaccine type matters for how high the peak is, though not necessarily for how fast it falls. Head-to-head comparisons found that mRNA vaccines produced significantly higher binding and neutralizing antibody responses than viral vector vaccines like Sputnik V, both in people who had never been infected and in those who had. The actual rate of antibody decay was similar between platforms, with a half-life of around five months across types. The difference was in the starting height: mRNA vaccines maintained their superiority through at least six months simply because they started higher.²⁰

There is a nuance, though. A comparative analysis of waning neutralizing antibody titers found that different platforms declined at different rates after the primary series. Heterologous (mix-and-match) primary series saw a faster fold-drop in titers per 90 days than viral vector vaccines, which declined more gradually.²¹ This is a case where “higher peak, faster fall” can sometimes leave different platforms roughly comparable a few months out, depending on the specific combination.

The Mucosal Immunity Gap

One often-overlooked reason vaccines do not prevent infection as well as they prevent severe disease is where the antibodies end up. All approved COVID vaccines are injected into muscle, and they primarily generate antibodies in the blood. But the virus enters through your nose and throat, where a different set of antibodies (mucosal antibodies) stands guard. Research comparing antibody levels in the nose, saliva, and blood found that nasal antibody levels declined more rapidly than blood antibody levels after vaccination in previously infected individuals. The vaccines boosted blood antibodies far more than nasal ones.²² This helps explain why vaccinated people can still catch the virus readily even when their blood antibody levels look decent: the frontline defense at the point of entry is not as well supplied.

Do Repeated Boosters Wear Out the Immune System?

A persistent worry is that repeated boosting could exhaust the immune system, training it to become less responsive over time. The evidence here is mostly reassuring for the general population. A study tracking older adults, immunosuppressed individuals with rheumatoid arthritis, and healthy adults found no significant increase in exhaustion markers on spike-specific T cells after a third or fourth vaccination compared to the second.²³

That said, the story may differ for certain groups. Among cancer patients receiving a third mRNA dose, researchers observed a split: about two-thirds saw their T cell response increase, but roughly a third showed a marked drop in virus-specific immune function after the booster. Those patients with a declining response had higher levels of exhaustion markers on their T cells, and the proportion of exhausted T cells inversely correlated with immune function.²⁴ This does not mean boosters are harmful for people with cancer, but it highlights that immune-suppressed populations deserve closer monitoring and possibly different strategies. A booster still augments both antibody and T cell responses in most people, even though those responses attenuate over time.²⁵

Vaccines and Long COVID Risk

Beyond preventing acute illness, vaccination appears to reduce the likelihood of developing long COVID after a breakthrough infection. A systematic review and meta-analysis of the evidence found that vaccination before infection was associated with lower long COVID risk, though the limited data examining the effect of time between vaccination and infection suggested that this protective effect may also wane.²⁶ If the protection against long COVID follows a similar trajectory to protection against infection, the benefit is strongest in the months immediately following vaccination and diminishes gradually. This is worth keeping in mind when deciding the timing of a booster relative to periods of higher exposure risk.

Defining a Protective Threshold

A natural question is whether there is a specific antibody level below which you are no longer protected. Researchers have tried to define this, and one household-contact study established a binding antibody threshold that correlated with protection against the Delta variant. The study’s authors noted, however, that different variants would likely have different thresholds, making any single cutoff a moving target rather than a fixed number.²⁷ And antibody levels alone miss the contribution of T cells and memory B cells, which cannot be measured with a simple blood draw. In practice, there is no consumer-friendly test that tells you “your immunity has expired,” which is part of why public health agencies base booster recommendations on population-level waning data and variant surveillance rather than individual antibody checks.